As an epidemiologist and physician, I’ve long been concerned about how health interventions for marginalized communities are evaluated. A new study explores that concern and offers some solutions for ...

Economic consequences of molecular profiling for metastatic solid tumors. Cost-effectiveness of pazopanib (PAZ) versus sunitinib (SUN) as first-line treatment of metastatic renal cell carcinoma (mRCC) ...

William Padula, PhD, MSc, MS, assistant professor of pharmaceutical and health economics, University of California Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, discusses the benefits ...

Multicancer early detection testing results in extended life-years and reduced cancer treatment costs through earlier diagnosis, leading to a cost-effective option in cancer screening. Objectives: ...